ROVI announces the agreement to market Hirobriz Breezhaler y Ulunar Breezhaler en España


No votes yet
 
Related
ROVI reports operating revenue growth of 8% and net profit growth of 83%
Today, Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), a pan-European pharmaceutical company specialising and engaging in the...
9 min
27/07/2020
ROVI and Moderna Announce Collaboration for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a...
3 min
09/07/2020